SEARCH

SEARCH BY CITATION

References

  • 1
    den Hertog J, Östman A & Böhmer F-D (2008) Protein tyrosine phosphatases: regulatory mechanisms. FEBS J 275, 831847.
  • 2
    Pulido R & Hooft van Huijsduijnen R (2008) Protein tyrosine phosphatases: dual-specificity phosphatases in health and disease. FEBS J 275, 848866.
  • 3
    Tabernero L, Aricescu A, Jones E & Szedlacsek S (2008) Protein tyrosine phosphatases: structure–function relationships. FEBS J 275, 867882.
  • 4
    Asante-Appiah E & Kennedy BP (2003) Protein tyrosine phosphatases: the quest for negative regulators of insulin action. Am J Physiol Endocrinol Metab 284, E663E670.
  • 5
    Dubois MJ, Bergeron S, Kim HJ, Dombrowski L, Perreault M, Fournes B, Faure R, Olivier M, Beauchemin N, Shulman GI et al. (2006) The SHP-1 protein tyrosine phosphatase negatively modulates glucose homeostasis. Nat Med 12, 549556.
  • 6
    Dube N & Tremblay ML (2005) Involvement of the small protein tyrosine phosphatases TC-PTP and PTP1B in signal transduction and diseases: from diabetes, obesity to cell cycle, and cancer. Biochim Biophys Acta 1754, 108117.
  • 7
    Cuppen E, Wijers M, Schepens J, Fransen J, Wieringa B & Hendriks W (1999) A FERM domain governs apical confinement of PTP-BL in epithelial cells. J Cell Sci 112, 32993308.
  • 8
    Tiganis T & Bennett AM (2007) Protein tyrosine phosphatase function: the substrate perspective. Biochem J 402, 115.
  • 9
    Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, Osterman A, Godzik A, Hunter T, Dixon J & Mustelin T (2004) Protein tyrosine phosphatases in the human genome. Cell 117, 699711.
  • 10
    Andersen JN, Mortensen OH, Peters GH, Drake PG, Iversen LF, Olsen OH, Jansen PG, Andersen HS, Tonks NK & Moller NPH (2001) Structural and evolutionary relationship among protein tyrosine phosphatase domains. Mol Cell Biol 21, 71177136.
  • 11
    Andersen JN, Jansen PG, Echwald SM, Mortensen OH, Fukada T, Del Vecchio R, Tonks NK & Moller NP (2004) A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage. FASEB J 18, 830.
  • 12
    Bult A, Zhao F, Dirkx R Jr, Sharma E, Lukacsi E, Solimena M, Naegele JR & Lombroso PJ (1996) STEP61: a member of a family of brain-enriched PTPs is localized to the endoplasmic reticulum. J Neurosci 16, 78217831.
  • 13
    Elson A & Leder P (1995) Identification of a cytoplasmic, phorbol ester-inducible isoform of protein tyrosine phosphatase epsilon. Proc Natl Acad Sci USA 92, 1223512239.
  • 14
    Seifert RA, Coats SA, Oganesian A, Wright MB, Dishmon M, Booth CJ, Johnson RJ, Alpers CE & Bowen-Pope DF (2003) PTPRQ is a novel phosphatidylinositol phosphatase that can be expressed as a cytoplasmic protein or as a subcellularly localized receptor-like protein. Exp Cell Res 287, 374386.
  • 15
    Chirivi RGS, Dilaver G, van de Vorstenbosch R, Wanschers B, Schepens J, Croes H, Fransen J & Hendriks W (2004) Characterization of multiple transcripts and isoforms derived from the mouse protein tyrosine phosphatase gene Ptprr. Genes Cells 9, 919933.
  • 16
    Trapasso F, Drusco A, Costinean S, Alder H, Aqeilan RI, Iuliano R, Gaudio E, Raso C, Zanesi N, Croce CM et al. (2006) Genetic ablation of Ptprj, a mouse cancer susceptibility gene, results in normal growth and development and does not predispose to spontaneous tumorigenesis. DNA Cell Biol 25, 376382.
  • 17
    Takahashi T, Takahashi K, St John PL, Fleming PA, Tomemori T, Watanabe T, Abrahamson DR, Drake CJ, Shirasawa T & Daniel TO (2003) A mutant receptor tyrosine phosphatase, CD148, causes defects in vascular development. Mol Cell Biol 23, 18171831.
  • 18
    Takahashi T, Takahashi K, Mernaugh RL, Tsuboi N, Liu H & Daniel TO (2006) A monoclonal antibody against CD148, a receptor-like tyrosine phosphatase, inhibits endothelial-cell growth and angiogenesis. Blood 108, 12341242.
  • 19
    Ruivenkamp CA, van Wezel T, Zanon C, Stassen AP, Vlcek C, Csikos T, Klous AM, Tripodis N, Perrakis A, Boerrigter L et al. (2002) Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. Nat Genet 31, 295300.
  • 20
    Ruivenkamp C, Hermsen M, Postma C, Klous A, Baak J, Meijer G & Demant P (2003) LOH of PTPRJ occurs early in colorectal cancer and is associated with chromosomal loss of 18q12-21. Oncogene 22, 34723474.
  • 21
    Iuliano R, Le Pera I, Cristofaro C, Baudi F, Arturi F, Pallante P, Martelli ML, Trapasso F, Chiariotti L & Fusco A (2004) The tyrosine phosphatase PTPRJ/DEP-1 genotype affects thyroid carcinogenesis. Oncogene 23, 84328438.
  • 22
    Lesueur F, Pharoah PD, Laing S, Ahmed S, Jordan C, Smith PL, Luben R, Wareham NJ, Easton DF, Dunning AM et al. (2005) Allelic association of the human homologue of the mouse modifier Ptprj with breast cancer. Hum Mol Genet 14, 23492356.
  • 23
    van Puijenbroek M, Dierssen JW, Stanssens P, van Eijk R, Cleton-Jansen AM, van Wezel T & Morreau H (2005) Mass spectrometry-based loss of heterozygosity analysis of single-nucleotide polymorphism loci in paraffin embedded tumors using the MassEXTEND assay: single-nucleotide polymorphism loss of heterozygosity analysis of the protein tyrosine phosphatase receptor type J in familial colorectal cancer. J Mol Diagn 7, 623630.
  • 24
    Luo L, Shen GQ, Stiffler KA, Wang QK, Pretlow TG & Pretlow TP (2006) Loss of heterozygosity in human aberrant crypt foci (ACF), a putative precursor of colon cancer. Carcinogenesis 27, 11531159.
  • 25
    Kubosaki A, Gross S, Miura J, Saeki K, Zhu M, Nakamura S, Hendriks W & Notkins AL (2004) Targeted disruption of the IA-2beta gene causes glucose intolerance and impairs insulin secretion but does not prevent the development of diabetes in NOD mice. Diabetes 53, 16841691.
  • 26
    Saeki K, Zhu M, Kubosaki A, Xie J, Lan MS & Notkins AL (2002) Targeted disruption of the protein tyrosine phosphatase-like molecule IA-2 results in alterations in glucose tolerance tests and insulin secretion. Diabetes 51, 18421850.
  • 27
    Kubosaki A, Nakamura S & Notkins AL (2005) Dense core vesicle proteins IA-2 and IA-2beta: metabolic alterations in double knockout mice. Diabetes 54(Suppl 2), S46S51.
  • 28
    Kubosaki A, Nakamura S, Clark A, Morris JF & Notkins AL (2006) Disruption of the transmembrane dense core vesicle proteins IA-2 and IA-2beta causes female infertility. Endocrinology 147, 811815.
  • 29
    Cai T, Fukushige T, Notkins AL & Krause M (2004) Insulinoma-associated protein IA-2, a vesicle transmembrane protein, genetically interacts with UNC-31/CAPS and affects neurosecretion in Caenorhabditis elegans. J Neurosci 24, 31153124.
  • 30
    Seet BT, Dikic I, Zhou MM & Pawson T (2006) Reading protein modifications with interaction domains. Nat Rev Mol Cell Biol 7, 473483.
  • 31
    Ort T, Voronov S, Guo J, Zawalich K, Froehner SC, Zawalich W & Solimena M (2001) Dephosphorylation of beta2-syntrophin and Ca2+/mu-calpain-mediated cleavage of ICA512 upon stimulation of insulin secretion. EMBO J 20, 40134023.
  • 32
    Harroch S, Palmeri M, Rosenbluth J, Custer A, Okigaki M, Shrager P, Blum M, Buxbaum JD & Schlessinger J (2000) No obvious abnormality in mice deficient in receptor protein tyrosine phosphatase beta. Mol Cell Biol 20, 77067715.
  • 33
    Lamprianou S, Vacaresse N, Suzuki Y, Meziane H, Buxbaum JD, Schlessinger J & Harroch S (2006) Receptor protein tyrosine phosphatase gamma is a marker for pyramidal cells and sensory neurons in the nervous system and is not necessary for normal development. Mol Cell Biol 26, 51065119.
  • 34
    Ponniah S, Wang DZ, Lim KL & Pallen CJ (1999) Targeted disruption of the tyrosine phosphatase PTPalpha leads to constitutive downregulation of the kinases Src and Fyn. Curr Biol 9, 535538.
  • 35
    Petrone A, Battaglia F, Wang C, Dusa A, Su J, Zagzag D, Bianchi R, Casaccia-Bonnefil P, Arancio O & Sap J (2003) Receptor protein tyrosine phosphatase alpha is essential for hippocampal neuronal migration and long-term potentiation. EMBO J 22, 41214131.
  • 36
    Peretz A, Gil-Henn H, Sobko A, Shinder V, Attali B & Elson A (2000) Hypomyelination and increased activity of voltage-gated K(+) channels in mice lacking protein tyrosine phosphatase epsilon. EMBO J 19, 40364045.
  • 37
    Tiran Z, Peretz A, Sines T, Shinder V, Sap J, Attali B & Elson A (2006) Tyrosine phosphatases epsilon and alpha perform specific and overlapping functions in regulation of voltage-gated potassium channels in Schwann cells. Mol Biol Cell 17, 43304342.
  • 38
    Uetani N, Chagnon MJ, Kennedy TE, Iwakura Y & Tremblay ML (2006) Mammalian motoneuron axon targeting requires receptor protein tyrosine phosphatases sigma and delta. J Neurosci 26, 58725880.
  • 39
    Uetani N, Kato K, Ogura H, Mizuno K, Kawano K, Mikoshiba K, Yakura H, Asano M & Iwakura Y (2000) Impaired learning with enhanced hippocampal long-term potentiation in PTPdelta-deficient mice. EMBO J 19, 27752785.
  • 40
    Dunah AW, Hueske E, Wyszynski M, Hoogenraad CC, Jaworski J, Pak DT, Simonetta A, Liu G & Sheng M (2005) LAR receptor protein tyrosine phosphatases in the development and maintenance of excitatory synapses. Nat Neurosci 8, 458467.
  • 41
    Dino MR, Harroch S, Hockfield S & Matthews RT (2006) Monoclonal antibody Cat-315 detects a glycoform of receptor protein tyrosine phosphatase beta/phosphacan early in CNS development that localizes to extrasynaptic sites prior to synapse formation. Neuroscience 142, 10551069.
  • 42
    Skarnes WC, Moss JE, Hurtley SM & Beddington RS (1995) Capturing genes encoding membrane and secreted proteins important for mouse development. Proc Natl Acad Sci USA 92, 65926596.
  • 43
    Schaapveld RQ, Schepens JT, Robinson GW, Attema J, Oerlemans FT, Fransen JA, Streuli M, Wieringa B, Hennighausen L & Hendriks WJ (1997) Impaired mammary gland development and function in mice lacking LAR receptor-like tyrosine phosphatase activity. Dev Biol 188, 134146.
  • 44
    Chagnon MJ, Uetani N & Tremblay ML (2004) Functional significance of the LAR receptor protein tyrosine phosphatase family in development and diseases. Biochem Cell Biol 82, 664675.
  • 45
    Yeo TT, Yang T, Massa SM, Zhang JS, Honkaniemi J, Butcher LL & Longo FM (1997) Deficient LAR expression decreases basal forebrain cholinergic neuronal size and hippocampal cholinergic innervation. J Neurosci Res 47, 348360.
  • 46
    Shultz LD, Schweitzer PA, Rajan TV, Yi T, Ihle JN, Matthews RJ, Thomas ML & Beier DR (1993) Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell 73, 14451454.
  • 47
    Tsui FW, Martin A, Wang J & Tsui HW (2006) Investigations into the regulation and function of the SH2 domain-containing protein-tyrosine phosphatase, SHP-1. Immunol Res 35, 127136.
  • 48
    Tsui HW, Siminovitch KA, de Souza L & Tsui FW (1993) Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. Nat Genet 4, 124129.
  • 49
    Arrandale JM, Gore-Willse A, Rocks S, Ren JM, Zhu J, Davis A, Livingston JN & Rabin DU (1996) Insulin signaling in mice expressing reduced levels of Syp. J Biol Chem 271, 2135321358.
  • 50
    Saxton TM, Henkemeyer M, Gasca S, Shen R, Rossi DJ, Shalaby F, Feng GS & Pawson T (1997) Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2. EMBO J 16, 23522364.
  • 51
    Yang W, Klaman LD, Chen B, Araki T, Harada H, Thomas SM, George EL & Neel BG (2006) An Shp2/SFK/Ras/Erk signaling pathway controls trophoblast stem cell survival. Dev Cell 10, 317327.
  • 52
    Neel BG, Gu H & Pao L (2003) The ‘Shp’ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 28, 284293.
  • 53
    Dong XP, Li XM, Gao TM, Zhang EE, Feng GS, Xiong WC & Mei L (2006) Shp2 is dispensable in the formation and maintenance of the neuromuscular junction. Neurosignals 15, 5363.
  • 54
    Pao LI, Lam KP, Henderson JM, Kutok JL, Alimzhanov M, Nitschke L, Thomas ML, Neel BG & Rajewsky K (2007) B cell-specific deletion of protein-tyrosine phosphatase Shp1 promotes B-1a cell development and causes systemic autoimmunity. Immunity 27, 3548.
  • 55
    Ke Y, Lesperance J, Zhang EE, Bard-Chapeau EA, Oshima RG, Muller WJ & Feng GS (2006) Conditional deletion of Shp2 in the mammary gland leads to impaired lobulo-alveolar outgrowth and attenuated Stat5 activation. J Biol Chem 281, 3437434380.
  • 56
    Zhang SQ, Yang W, Kontaridis MI, Bivona TG, Wen G, Araki T, Luo J, Thompson JA, Schraven BL, Philips MR et al. (2004) Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol Cell 13, 341355.
  • 57
    Glaser S, Anastassiadis K & Stewart AF (2005) Current issues in mouse genome engineering. Nat Genet 37, 11871193.
  • 58
    Salmond RJ, Huyer G, Kotsoni A, Clements L & Alexander DR (2005) The src homology 2 domain-containing tyrosine phosphatase 2 regulates primary T-dependent immune responses and Th cell differentiation. J Immunol 175, 64986508.
  • 59
    Mohi MG & Neel BG (2007) The role of Shp2 (PTPN11) in cancer. Curr Opin Genet Dev 17, 2330.
  • 60
    Gelb BD & Tartaglia M (2006) Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. Hum Mol Genet 15(Spec No 2), R220R226.
  • 61
    Edouard T, Montagner A, Dance M, Conte F, Yart A, Parfait B, Tauber M, Salles JP & Raynal P (2007) How do Shp2 mutations that oppositely influence its biochemical activity result in syndromes with overlapping symptoms? Cell Mol Life Sci 64, 15851590.
  • 62
    Tonks NK (2006) Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 7, 833846.
  • 63
    Oganesian A, Poot M, Daum G, Coats SA, Wright MB, Seifert RA & Bowen-Pope DF (2003) Protein tyrosine phosphatase RQ is a phosphatidylinositol phosphatase that can regulate cell survival and proliferation. Proc Natl Acad Sci USA 100, 75637568.
  • 64
    Wang Z, Shen D, Parsons DW, Bardelli A, Sager J, Szabo S, Ptak J, Silliman N, Peters BA, van der Heijden MS et al. (2004) Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 304, 11641166.
  • 65
    Lee JW, Jeong EG, Lee SH, Nam SW, Kim SH, Lee JY & Yoo NJ (2007) Mutational analysis of PTPRT phosphatase domains in common human cancers. Apmis 115, 4751.
  • 66
    Stallings RL, Nair P, Maris JM, Catchpoole D, McDermott M, O’Meara A & Breatnach F (2006) High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma. Cancer Res 66, 36733680.
  • 67
    Purdie KJ, Lambert SR, Teh MT, Chaplin T, Molloy G, Raghavan M, Kelsell DP, Leigh IM, Harwood CA, Proby CM et al. (2007) Allelic imbalances and microdeletions affecting the PTPRD gene in cutaneous squamous cell carcinomas detected using single nucleotide polymorphism microarray analysis. Genes Chromosomes Cancer 46, 661669.
  • 68
    Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L, Beheshti J, Lee JC, Naoki K, Richards WG et al. (2005) Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res 65, 55615570.
  • 69
    Dube N, Bourdeau A, Heinonen KM, Cheng A, Loy AL & Tremblay ML (2005) Genetic ablation of protein tyrosine phosphatase 1B accelerates lymphomagenesis of p53-null mice through the regulation of B-cell development. Cancer Res 65, 1008810095.
  • 70
    Julien SG, Dube N, Read M, Penney J, Paquet M, Han Y, Kennedy BP, Muller WJ & Tremblay ML (2007) Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. Nat Genet 39, 338346.
  • 71
    Bentires-Alj M & Neel BG (2007) Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer. Cancer Res 67, 24202424.
  • 72
    Tonks NK & Muthuswamy SK (2007) A brake becomes an accelerator: PTP1B – a new therapeutic target for breast cancer. Cancer Cell 11, 214216.
  • 73
    Elson A (1999) Protein tyrosine phosphatase epsilon increases the risk of mammary hyperplasia and mammary tumors in transgenic mice. Oncogene 18, 75357542.
  • 74
    Gil-Henn H & Elson A (2003) Tyrosine phosphatase-epsilon activates Src and supports the transformed phenotype of Neu-induced mammary tumor cells. J Biol Chem 278, 1557915586.
  • 75
    Berman-Golan D & Elson A (2007) Neu-mediated phosphorylation of protein tyrosine phosphatase epsilon is critical for activation of Src in mammary tumor cells. Oncogene 26, 70287037.
  • 76
    Östman A, Hellberg C & Böhmer FD (2006) Protein-tyrosine phosphatases and cancer. Nat Rev Cancer 6, 307320.
  • 77
    Mustelin T, Vang T & Bottini N (2005) Protein tyrosine phosphatases and the immune response. Nat Rev Immunol 5, 4357.
  • 78
    Dolton GM, Sathish JG & Matthews RJ (2006) Protein tyrosine phosphatases as negative regulators of the immune response. Biochem Soc Trans 34, 10411045.
  • 79
    Pao LI, Badour K, Siminovitch KA & Neel BG (2007) Nonreceptor protein-tyrosine phosphatases in immune cell signaling. Annu Rev Immunol 25, 473523.
  • 80
    Majeti R, Xu Z, Parslow TG, Olson JL, Daikh DI, Killeen N & Weiss A (2000) An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity. Cell 103, 10591070.
  • 81
    Hasegawa K, Martin F, Huang G, Tumas D, Diehl L & Chan AC (2004) PEST domain-enriched tyrosine phosphatase (PEP) regulation of effector/memory T cells. Science 303, 685689.
  • 82
    Vang T, Miletic AV, Bottini N & Mustelin T (2007) Protein tyrosine phosphatase PTPN22 in human autoimmunity. Autoimmunity 40, 453461.
  • 83
    Wise CA, Gillum JD, Seidman CE, Lindor NM, Veile R, Bashiardes S & Lovett M (2002) Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 11, 961969.
  • 84
    Persson C, Savenhed C, Bourdeau A, Tremblay ML, Markova B, Bohmer FD, Haj FG, Neel BG, Elson A, Heldin CH et al. (2004) Site-selective regulation of platelet-derived growth factor beta receptor tyrosine phosphorylation by T-cell protein tyrosine phosphatase. Mol Cell Biol 24, 21902201.
  • 85
    Moffat J & Sabatini DM (2006) Building mammalian signalling pathways with RNAi screens. Nat Rev Mol Cell Biol 7, 177187.
  • 86
    Majeti R, Bilwes AM, Noel JP, Hunter T & Weiss A (1998) Dimerization-induced inhibition of receptor protein tyrosine phosphatase function through an inhibitory wedge. Science 279, 8891.
  • 87
    Bilwes AM, den Hertog J, Hunter T & Noel JP (1996) Structural basis for inhibition of receptor protein-tyrosine phosphatase-alpha by dimerization. Nature 382, 555559.
  • 88
    Xie Y, Massa SM, Ensslen-Craig SE, Major DL, Yang T, Tisi MA, Derevyanny VD, Runge WO, Mehta BP, Moore LA et al. (2006) Protein-tyrosine phosphatase (PTP) wedge domain peptides: a novel approach for inhibition of PTP function and augmentation of protein-tyrosine kinase function. J Biol Chem 281, 1648216492.
  • 89
    Chin CN, Sachs JN & Engelman DM (2005) Transmembrane homodimerization of receptor-like protein tyrosine phosphatases. FEBS Lett 579, 38553858.
  • 90
    Gross S, Blanchetot C, Schepens J, Albet S, Lammers R, den Hertog J & Hendriks W (2002) Multimerization of the protein-tyrosine phosphatase (PTP)-like insulin-dependent diabetes mellitus autoantigens IA-2 and IA-2beta with receptor PTPs (RPTPs). Inhibition of RPTPalpha enzymatic activity. J Biol Chem 277, 4813948145.
  • 91
    Yin H, Slusky JS, Berger BW, Walters RS, Vilaire G, Litvinov RI, Lear JD, Caputo GA, Bennett JS & DeGrado WF (2007) Computational design of peptides that target transmembrane helices. Science 315, 181718122.
  • 92
    Lee S, Faux C, Nixon J, Alete D, Chilton J, Hawadle M & Stoker AW (2007) Dimerization of protein tyrosine phosphatase sigma governs both ligand binding and isoform specificity. Mol Cell Biol 27, 17951808.
  • 93
    Yang T, Yin W, Derevyanny VD, Moore LA & Longo FM (2005) Identification of an ectodomain within the LAR protein tyrosine phosphatase receptor that binds homophilically and activates signalling pathways promoting neurite outgrowth. Eur J Neurosci 22, 21592170.
  • 94
    Paul S, Olausson P, Venkitaramani DV, Ruchkina I, Moran TD, Tronson N, Mills E, Hakim S, Salter MW, Taylor JR et al. (2007) The striatal-enriched protein tyrosine phosphatase gates long-term potentiation and fear memory in the lateral amygdala. Biol Psychiatry 61, 10491061.
  • 95
    Rashid-Doubell F, McKinnell I, Aricescu AR, Sajnani G & Stoker A (2002) Chick PTPsigma regulates the targeting of retinal axons within the optic tectum. J Neurosci 22, 50245033.
  • 96
    Bourdeau A, Dube N & Tremblay ML (2005) Cytoplasmic protein tyrosine phosphatases, regulation and function: the roles of PTP1B and TC-PTP. Curr Opin Cell Biol 17, 203209.
  • 97
    Bauler TJ, Hughes ED, Arimura Y, Mustelin T, Saunders TL & King PD (2007) Normal TCR signal transduction in mice that lack catalytically active PTPN3 protein tyrosine phosphatase. J Immunol 178, 36803687.
  • 98
    Pilecka I, Patrignani C, Pescini R, Curchod M-L, Perrin D, Xue Y, Yasenchak J, Clark A, Magnone M, Zaratin P et al. (2007) Protein tyrosine phosphatase H1 (PTP-H1/PTPN3) controls growth hormone receptor signaling and systemic growth. J Biol Chem 282, 3540535415.
  • 99
    Kina S, Tezuka T, Kusakawa S, Kishimoto Y, Kakizawa S, Hashimoto K, Ohsugi M, Kiyama Y, Horai R, Sudo K et al. (2007) Involvement of protein-tyrosine phosphatase PTPMEG in motor learning and cerebellar long-term depression. Eur J Neurosci 26, 22692278.
  • 100
    Braithwaite SP, Paul S, Nairn AC & Lombroso PJ (2006) Synaptic plasticity: one STEP at a time. Trends Neurosci 29, 452458.
  • 101
    Choi YS, Lin SL, Lee B, Kurup P, Cho HY, Naegele JR, Lombroso PJ & Obrietan K (2007) Status epilepticus-induced somatostatinergic hilar interneuron degeneration is regulated by striatal enriched protein tyrosine phosphatase. J Neurosci 27, 29993009.
  • 102
    Umeda S, Beamer WG, Takagi K, Naito M, Hayashi S, Yonemitsu H, Yi T & Shultz LD (1999) Deficiency of SHP-1 protein-tyrosine phosphatase activity results in heightened osteoclast function and decreased bone density. Am J Pathol 155, 223233.
  • 103
    Wu C, Sun M, Liu L & Zhou GW (2003) The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene 306, 112.
  • 104
    Gronda M, Arab S, Iafrate B, Suzuki H & Zanke BW (2001) Hematopoietic protein tyrosine phosphatase suppresses extracellular stimulus-regulated kinase activation. Mol Cell Biol 21, 68516858.
  • 105
    Wang Y, Vachon E, Zhang J, Cherepanov V, Kruger J, Li J, Saito K, Shannon P, Bottini N, Huynh H et al. (2005) Tyrosine phosphatase MEG2 modulates murine development and platelet and lymphocyte activation through secretory vesicle function. J Exp Med 202, 15871597.
  • 106
    Araki T, Mohi MG, Ismat FA, Bronson RT, Williams IR, Kutok JL, Yang W, Pao LI, Gilliland DG, Epstein JA et al. (2004) Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med 10, 849857.
  • 107
    Sarkozy A, Obregon MG, Conti E, Esposito G, Mingarelli R, Pizzuti A & Dallapiccola B (2004) A novel PTPN11 gene mutation bridges Noonan syndrome, multiple lentigines/LEOPARD syndrome and Noonan-like/multiple giant cell lesion syndrome. Eur J Hum Genet 12, 10691072.
  • 108
    Sirois J, Cote JF, Charest A, Uetani N, Bourdeau A, Duncan SA, Daniels E & Tremblay ML (2006) Essential function of PTP-PEST during mouse embryonic vascularization, mesenchyme formation, neurogenesis and early liver development. Mech Dev 123, 869880.
  • 109
    Nakahira M, Tanaka T, Robson BE, Mizgerd JP & Grusby MJ (2007) Regulation of signal transducer and activator of transcription signaling by the tyrosine phosphatase PTP-BL. Immunity 26, 163176.
  • 110
    Wansink DG, Peters W, Schaafsma I, Sutmuller RP, Oerlemans F, Adema GJ, Wieringa B, van der Zee CE & Hendriks W (2004) Mild impairment of motor nerve repair in mice lacking PTP-BL tyrosine phosphatase activity. Physiol Genom 19, 5060.
  • 111
    Nedachi T & Conti M (2004) Potential role of protein tyrosine phosphatase nonreceptor type 13 in the control of oocyte meiotic maturation. Development 131, 49874998.
  • 112
    Ogata M, Takada T, Mori Y, Uchida Y, Miki T, Okuyama A, Kosugi A, Sawada M, Oh-hora M & Hamaoka T (1999) Regulation of phosphorylation level and distribution of PTP36, a putative protein tyrosine phosphatase, by cell-substrate adhesion. J Biol Chem 274, 2071720724.
  • 113
    Gensler M, Buschbeck M & Ullrich A (2004) Negative regulation of HER2 signaling by the PEST-type protein-tyrosine phosphatase BDP1. J Biol Chem 279, 1211012116.
  • 114
    Fodero-Tavoletti MT, Hardy MP, Cornell B, Katsis F, Sadek CM, Mitchell CA, Kemp BE & Tiganis T (2005) Protein tyrosine phosphatase hPTPN20a is targeted to sites of actin polymerization. Biochem J 389, 343354.
  • 115
    Jui HY, Tseng RJ, Wen X, Fang HI, Huang LM, Chen KY, Kung HJ, Ann DK & Shih HM (2000) Protein-tyrosine phosphatase D1, a potential regulator and effector for Tec family kinases. J Biol Chem 275, 4112441132.
  • 116
    Toyooka S, Ouchida M, Jitsumori Y, Tsukuda K, Sakai A, Nakamura A, Shimizu N & Shimizu K (2000) HD-PTP: a novel protein tyrosine phosphatase gene on human chromosome 3p21.3. Biochem Biophys Res Commun 278, 671678.
  • 117
    Castiglioni S, Maier JA & Mariotti M (2007) The tyrosine phosphatase HD-PTP: a novel player in endothelial migration. Biochem Biophys Res Commun 364, 534539.
  • 118
    Skelton MR, Ponniah S, Wang DZ, Doetschman T, Vorhees CV & Pallen CJ (2003) Protein tyrosine phosphatase alpha (PTP alpha) knockout mice show deficits in Morris water maze learning, decreased locomotor activity, and decreases in anxiety. Brain Res 984, 110.
  • 119
    Bodrikov V, Leshchyns’ka I, Sytnyk V, Overvoorde J, den Hertog J & Schachner M (2005) RPTPalpha is essential for NCAM-mediated p59fyn activation and neurite elongation. J Cell Biol 168, 127139.
  • 120
    Su J, Muranjan M & Sap J (1999) Receptor protein tyrosine phosphatase alpha activates Src-family kinases and controls integrin-mediated responses in fibroblasts. Curr Biol 9, 505511.
  • 121
    Dominguez MG, Hughes VC, Pan L, Simmons M, Daly C, Anderson K, Noguera-Troise I, Murphy AJ, Valenzuela DM, Davis S et al. (2007) Vascular endothelial tyrosine phosphatase (VE-PTP)-null mice undergo vasculogenesis but die embryonically because of defects in angiogenesis. Proc Natl Acad Sci USA 104, 32433248.
  • 122
    Baumer S, Keller L, Holtmann A, Funke R, August B, Gamp A, Wolburg H, Wolburg-Buchholz K, Deutsch U & Vestweber D (2006) Vascular endothelial cell-specific phosphotyrosine phosphatase (VE-PTP) activity is required for blood vessel development. Blood 107, 47544762.
  • 123
    Alexander DR (2000) The CD45 tyrosine phosphatase: a positive and negative regulator of immune cell function. Semin Immunol 12, 349359.
  • 124
    Nakahara J, Seiwa C, Tan-Takeuchi K, Gotoh M, Kishihara K, Ogawa M, Asou H & Aiso S (2005) Involvement of CD45 in central nervous system myelination. Neurosci Lett 379, 116121.
  • 125
    Chiusaroli R, Knobler H, Luxenburg C, Sanjay A, Granot-Attas S, Tiran Z, Miyazaki T, Harmelin A, Baron R & Elson A (2004) Tyrosine phosphatase epsilon is a positive regulator of osteoclast function in vitro and in vivo. Mol Biol Cell 15, 234244.
  • 126
    Sully V, Pownall S, Vincan E, Bassal S, Borowski AH, Hart PH, Rockman SP & Phillips WA (2001) Functional abnormalities in protein tyrosine phosphatase epsilon-deficient macrophages. Biochem Biophys Res Commun 286, 184188.
  • 127
    Kolkman MJ, Streijger F, Linkels M, Bloemen M, Heeren DJ, Hendriks WJ & Van der Zee CE (2004) Mice lacking leukocyte common antigen-related (LAR) protein tyrosine phosphatase domains demonstrate spatial learning impairment in the two-trial water maze and hyperactivity in multiple behavioural tests. Behav Brain Res 154, 171182.
  • 128
    Bernabeu R, Yang T, Xie Y, Mehta B, Ma SY & Longo FM (2006) Downregulation of the LAR protein tyrosine phosphatase receptor is associated with increased dentate gyrus neurogenesis and an increased number of granule cell layer neurons. Mol Cell Neurosci 31, 723738.
  • 129
    Niu XL, Li J, Hakim ZS, Rojas M, Runge MS & Madamanchi NR (2007) Lar deficiency enhances IGF-1 signaling in vascular smooth muscle cells and promotes neointima formation in response to vascular injury. J Biol Chem 282, 1980819819.
  • 130
    Panagopoulos I, Pandis N, Thelin S, Petersson C, Mertens F, Borg A, Kristoffersson U, Mitelman F & Aman P (1996) The FHIT and PTPRG genes are deleted in benign proliferative breast disease associated with familial breast cancer and cytogenetic rearrangements of chromosome band 3p14. Cancer Res 56, 48714875.
  • 131
    van Doorn R, Zoutman WH, Dijkman R, de Menezes RX, Commandeur S, Mulder AA, van der Velden PA, Vermeer MH, Willemze R, Yan PS et al. (2005) Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol 23, 38863896.
  • 132
    Noguchi T, Tsuda M, Takeda H, Takada T, Inagaki K, Yamao T, Fukunaga K, Matozaki T & Kasuga M (2001) Inhibition of cell growth and spreading by stomach cancer-associated protein-tyrosine phosphatase-1 (SAP-1) through dephosphorylation of p130cas. J Biol Chem 276, 1521615224.
  • 133
    Kose H, Sakai T, Tsukumo S, Wei K, Yamada T, Yasutomo K & Matsumoto K (2007) Maturational arrest of thymocyte development is caused by a deletion in the receptor-like protein tyrosine phosphatase kappa gene in LEC rats. Genomics 89, 673677.
  • 134
    Nakamura M, Kishi M, Sakaki T, Hashimoto H, Nakase H, Shimada K, Ishida E & Konishi N (2003) Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas. Cancer Res 63, 737741.
  • 135
    Koop EA, Gebbink MF, Sweeney TE, Mathy MJ, Heijnen HF, Spaan JA, Voest EE, VanBavel E & Peters SL (2005) Impaired flow-induced dilation in mesenteric resistance arteries from receptor protein tyrosine phosphatase-mu-deficient mice. Am J Physiol Heart Circ Physiol 288, H1218H1223.
  • 136
    Koop EA, Lopes SM, Feiken E, Bluyssen HA, van der Valk M, Voest EE, Mummery CL, Moolenaar WH & Gebbink MF (2003) Receptor protein tyrosine phosphatase mu expression as a marker for endothelial cell heterogeneity; analysis of RPTPmu gene expression using LacZ knock-in mice. Int J Dev Biol 47, 345354.
  • 137
    Wharram BL, Goyal M, Gillespie PJ, Wiggins JE, Kershaw DB, Holzman LB, Dysko RC, Saunders TL, Samuelson LC & Wiggins RC (2000) Altered podocyte structure in GLEPP1 (Ptpro)-deficient mice associated with hypertension and low glomerular filtration rate. J Clin Invest 106, 12811290.
  • 138
    Motiwala T, Majumder S, Kutay H, Smith DS, Neuberg DS, Lucas DM, Byrd JC, Grever M & Jacob ST (2007) Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia. Clin Cancer Res 13, 31743181.
  • 139
    Goodyear RJ, Legan PK, Wright MB, Marcotti W, Oganesian A, Coats SA, Booth CJ, Kros CJ, Seifert RA, Bowen-Pope DF et al. (2003) A receptor-like inositol lipid phosphatase is required for the maturation of developing cochlear hair bundles. J Neurosci 23, 92089219.
  • 140
    Chirivi RG, Noordman YE, Van der Zee CE & Hendriks WJ (2007) Altered MAP kinase phosphorylation and impaired motor coordination in PTPRR deficient mice. J Neurochem 101, 829840.
  • 141
    Sapieha PS, Duplan L, Uetani N, Joly S, Tremblay ML, Kennedy TE & Di Polo A (2005) Receptor protein tyrosine phosphatase sigma inhibits axon regrowth in the adult injured CNS. Mol Cell Neurosci 28, 625635.
  • 142
    Batt J, Asa S, Fladd C & Rotin D (2002) Pituitary, pancreatic and gut neuroendocrine defects in protein tyrosine phosphatase-sigma-deficient mice. Mol Endocrinol 16, 155169.
  • 143
    Elchebly M, Wagner J, Kennedy TE, Lanctot C, Michaliszyn E, Itie A, Drouin J & Tremblay ML (1999) Neuroendocrine dysplasia in mice lacking protein tyrosine phosphatase sigma. Nat Genet 21, 330333.
  • 144
    McLean J, Batt J, Doering LC, Rotin D & Bain JR (2002) Enhanced rate of nerve regeneration and directional errors after sciatic nerve injury in receptor protein tyrosine phosphatase sigma knock-out mice. J Neurosci 22, 54815491.
  • 145
    Meathrel K, Adamek T, Batt J, Rotin D & Doering LC (2002) Protein tyrosine phosphatase sigma-deficient mice show aberrant cytoarchitecture and structural abnormalities in the central nervous system. J Neurosci Res 70, 2435.
  • 146
    Thompson KM, Uetani N, Manitt C, Elchebly M, Tremblay ML & Kennedy TE (2003) Receptor protein tyrosine phosphatase sigma inhibits axonal regeneration and the rate of axon extension. Mol Cell Neurosci 23, 681692.
  • 147
    Chagnon MJ, Elchebly M, Uetani N, Dombrowski L, Cheng A, Mooney RA, Marette A & Tremblay ML (2006) Altered glucose homeostasis in mice lacking the receptor protein tyrosine phosphatase sigma. Can J Physiol Pharmacol 84, 755763.
  • 148
    Muise AM, Walters T, Wine E, Griffiths AM, Turner D, Duerr RH, Regueiro MD, Ngan BY, Xu W, Sherman PM et al. (2007) Protein-tyrosine phosphatase sigma is associated with ulcerative colitis. Curr Biol 17, 12121218.
  • 149
    Zhang X, Guo A, Yu J, Possemato A, Chen Y, Zheng W, Polakiewicz RD, Kinzler KW, Vogelstein B, Velculescu VE et al. (2007) Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T. Proc Natl Acad Sci USA 104, 40604064.
  • 150
    Besco JA, Hooft van Huijsduijnen R, Frostholm A & Rotter A (2006) Intracellular substrates of brain-enriched receptor protein tyrosine phosphatase rho (RPTPrho/PTPRT). Brain Res 1116, 5057.
  • 151
    Yan HX, Yang W, Zhang R, Chen L, Tang L, Zhai B, Liu SQ, Cao HF, Man XB, Wu HP et al. (2006) Protein-tyrosine phosphatase PCP-2 inhibits beta-catenin signaling and increases E-cadherin-dependent cell adhesion. J Biol Chem 281, 1542315433.
  • 152
    Doumont G, Martoriati A, Beekman C, Bogaerts S, Mee PJ, Bureau F, Colombo E, Alcalay M, Bellefroid E, Marchesi F et al. (2005) G1 checkpoint failure and increased tumor susceptibility in mice lacking the novel p53 target Ptprv. EMBO J 24, 30933103.
  • 153
    Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY et al. (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130, 456469.
  • 154
    Doumont G, Martoriati A & Marine JC (2005) PTPRV is a key mediator of p53-induced cell cycle exit. Cell Cycle 4, 17031705.
  • 155
    Fujikawa A, Shirasaka D, Yamamoto S, Ota H, Yahiro K, Fukada M, Shintani T, Wada A, Aoyama N, Hirayama T et al. (2003) Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of Helicobacter pylori. Nat Genet 33, 375381.
  • 156
    Harroch S, Furtado GC, Brueck W, Rosenbluth J, Lafaille J, Chao M, Buxbaum JD & Schlessinger J (2002) A critical role for the protein tyrosine phosphatase receptor type Z in functional recovery from demyelinating lesions. Nat Genet 32, 411414.